51
|
Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†. Ann Oncol 2014; 25:1122-7. [PMID: 24669015 DOI: 10.1093/annonc/mdu124] [Citation(s) in RCA: 78] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Everolimus synergistically enhances taxane-induced cytotoxicity in breast cancer cells in vitro and in vivo in addition to demonstrating a direct antiproliferative activity. We aim to determine pharmacodynamics changes and response of adding everolimus to standard neoadjuvant chemotherapy in triple-negative breast cancer (TNBC). PATIENTS AND METHODS Phase II study in patients with primary TNBC randomized to T-FEC (paclitaxel 80 mg/m(2) i.v. weekly for 12 weeks, followed by 5-fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), and cyclophosphamide 500 mg/m(2) every 3 weeks for four cycles) versus TR-FEC (paclitaxel 80 mg/m(2) i.v. and everolimus 30 mg PO weekly for 12 weeks, followed by FEC). Tumor samples were collected to assess molecular changes in the PI3K/AKT/mTOR pathway, at baseline, 48 h, 12 weeks, and at surgery by reverse phase protein arrays (RPPA). Clinical end points included 12-week clinical response rate (12-week RR), pathological complete response (pCR), and toxicity. RESULTS Sixty-two patients were registered, and 50 were randomized, 27 received T-FEC, and 23 received TR-FEC. Median age was 48 (range 31-75). There was downregulation of the mTOR pathway at 48 h in the TR-FEC arm. Twelve-week RR by ultrasound were 29.6% versus 47.8%, (P = 0.075), and pCR were 25.9% versus 30.4% (P = 0.76) for T-FEC and TR-FEC, respectively. mTOR downregulation at 48 h did not correlate with 12-week RR in the TR-FEC group (P = 0.58). Main NCI grade 3/4 toxicities included anemia, neutropenia, rash/desquamation, and vomiting in both arms. There was one case of grade 3 pneumonitis in the TR-FEC arm. No grade 3/4 stomatitis occurred. CONCLUSION The addition of everolimus to paclitaxel was well tolerated. Everolimus downregulated mTOR signaling but downregulation of mTOR at 48 h did not correlate with 12-week RR in the TR-FEC group. CLINICAL TRIAL NUMBER NCT00499603.
Collapse
|
52
|
Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-MacGregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol 2013; 25:384-91. [PMID: 24351399 DOI: 10.1093/annonc/mdt525] [Citation(s) in RCA: 92] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Subtypes defined by hormonal receptor (HR) and HER2 status have not been well studied in inflammatory breast cancer (IBC). We characterized clinical parameters and long-term outcomes, and compared pathological complete response (pCR) rates by HR/HER2 subtype in a large IBC patient population. We also compared disease-free survival (DFS) and overall survival (OS) between IBC patients who received targeted therapies (anti-hormonal, anti-HER2) and those who did not. PATIENTS AND METHODS We retrospectively reviewed the records of patients diagnosed with IBC and treated at MD Anderson Cancer Center from January 1989 to January 2011. Of those, 527 patients had received neoadjuvant chemotherapy and had available information on estrogen receptor (ER), progesterone receptor (PR), and HER2 status. HR status was considered positive if either ER or PR status was positive. Using the Kaplan-Meier method, we estimated median DFS and OS durations from the time of definitive surgery. Using the Cox proportional hazards regression model, we determined the effect of prognostic factors on DFS and OS. Results were compared by subtype. RESULTS The overall pCR rate in stage III IBC was 15.2%, with the HR-positive/HER2-negative subtype showing the lowest rate (7.5%) and the HR-negative/HER2-positive subtype, the highest (30.6%). The HR-negative, HER2-negative subtype (triple-negative breast cancer, TNBC) had the worst survival rate. HR-positive disease, irrespective of HER2 status, had poor prognosis that did not differ from that of the HR-negative/HER2-positive subtype with regard to OS or DFS. Achieving pCR, no evidence of vascular invasion, non-TNBC, adjuvant hormonal therapy, and radiotherapy were associated with longer DFS and OS. CONCLUSIONS Hormone receptor and HER2 molecular subtypes had limited predictive and prognostic power in our IBC population. All molecular subtypes of IBC had a poor prognosis. HR-positive status did not necessarily confer a good prognosis. For all IBC subtypes, novel, specific treatment strategies are needed in the neoadjuvant and adjuvant settings.
Collapse
|
53
|
Murthy RK, Schover LR, Theriault RL, Valero V, Woodard TL, Hodge S, Litton JK. Abstract P3-11-02: Women with pregnancy-associated early breast cancer achieve improved emotional well-being as a result of their cancer experience. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-11-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Pregnancy-associated early breast cancer (PAEBC) has increased in incidence as more women pursue childbearing at an older age. The objective of this study was to measure the impact of diagnosis and treatment on emotional health and evaluate the positive emotional outcomes in a group of women with PAEBC. Methods: Between 1989 and 2010, 81 patients were treated for PAEBC with 5-flurouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy. Patients completed the Impact of Events Scale-Revised (IES-R), which is a questionnaire that measures subjective distress caused by traumatic events and the Post-traumatic Growth Inventory (PGI), which measures positive outcomes after a traumatic event. Results: Of the 81 women, 53% (43/81) completed the IES-R and 44% (36/81) also completed the PGI. The time since diagnosis ranged from 6 months to greater than 5 years. The median age of the participants was 33 years (range 26-43 years). Of the 43 patients who completed the IES-R, 91% (39/43) did not use avoidance as a primary coping strategy; they felt well equipped to deal with feelings about their diagnosis and treatment. Of patients who inadvertently thought about their diagnosis, 70% (30/43) noted that they avoided becoming upset by their thoughts. Less than 10% (9/43) of patients surveyed felt apathetic towards their diagnosis and subsequent treatment. In terms of positive outcomes, 94% (33/36) felt they were enabled to depend on others in times of crises and felt a greater appreciation for people and their kindness following their diagnosis of PAEBC. Eighty-six percent (31/36) had changed their priorities about what is important in life, felt more compassionate towards others, and felt a greater appreciation for the value of their own life. In addition, 86% (30/36) of patients indicated that they had discovered their inner strength and felt more inclined to change things in their life. Finally, 75% of patients surveyed felt they had developed a stronger religious faith because of their experience and had a better understanding of spiritual matters. The majority of patients reported improvement in interpersonal skills – placing more effort into their relationships and sharing a greater sense of closeness with others. Conclusions: Although women who experience PAEBC are thought to be at high risk for experiencing psychosocial distress, these findings suggest that most do not suffer negative emotional consequences; in fact, these data suggest that they often achieve improved emotional well-being as a result of their cancer experience. It is possible that these women have better emotional outcomes because they have successfully carried a pregnancy while facing a life-threatening illness. Comparisons to other premenopausal breast cancer survivors will be crucial in interpreting these findings.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-11-02.
Collapse
|
54
|
Barcenas CH, Niu J, Valero V, Smith B, Giordano SH. Abstract P3-06-02: The use of imaging and tumor markers in the staging of patients age <65 years with early-stage breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-06-02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose
Guidelines from the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) recommend against the use of positron emission tomography (PET), computed tomography (CT), radionuclide bone scans (RBS) and tumor markers (TM) in the staging of early-stage breast cancer with a low risk for distant metastasis. No previous studies have described the use of these tests or identified factors associated with this practice in patients age <65 years.
Methods
We used the national employer-based claims database MarketScan to identify patients with a first diagnosis of breast cancer, age 20 to 64 years, who had undergone a mastectomy or a lumpectomy, and a sentinel lymph node biopsy between the years of 2005 and 2010. We excluded patients who had undergone an axillary lymph node dissection, as this may indicate advanced nodal disease for which staging tests may be recommended. We ascertained claims for PET, CT, RBS and TM during the period of 3 months before and 1 month after the date of surgery. We used a multivariable logistic regression model to identify factors associated with the use of these tests. The variables included in the model were: age at diagnosis, geographic region, year of diagnosis, type of surgery (lumpectomy vs. mastectomy), endocrine therapy (yes vs. no), radiation therapy (yes vs. no), and chemotherapy (trastuzumab-based, non-trastuzumab-based, vs. no).
Results
We identified 42,606 patients (median age 53 years) of whom 12% had at least one claim for a PET, 6.5% for a CT, and 2.5% for TM. In combination, 17% of the patients had at least one claim for a test. Among patients diagnosed in 2005, 14% had claims for tests, whereas between 2006 and 2010, this proportion ranged between 16% and 18% (test for trend p-value: 0.08). Among patients who had chemotherapy, 22% of those who received trastuzumab-based regimens and 21% of those who received non-trastuzumab-based regimens had claims for tests, compared to 14% of patients who did not receive chemotherapy. In the regression analysis, we observed geographic differences, where patients from the Northeast had increased odds of testing, compared to patients from the North Central region (odds ratio [OR] 1.46, 95% confidence interval [CI] 1.34 - 1.59). Patients who underwent a lumpectomy had decreased odds of testing, compared to those who had a mastectomy (OR 0.62, 95% CI 0.57 - 0.66). Patients who received radiation therapy (OR 1.30; 95% CI 1.20 - 1.40) and chemotherapy (non-trastuzumab-based: OR 1.67, 95% CI 1.58 - 1.77; trastuzumab-based: OR 1.69, 95% CI 1.55 - 1.84) had increased odds of testing.
Conclusion
Despite current ASCO and NCCN guidelines, the use of imaging tests and TM in the staging of early-stage breast cancer remains common, and there is no clear trend of a change of this non-recommended practice over time. Subsets of patients with early-stage breast cancer had an increased probability of undergoing tests not recommended for staging purposes. The use of imaging tests and TM may be increased in those patients who are perceived to be at a higher risk for metastasis during diagnosis, as there was a significant association of this practice with mastectomy (over lumpectomy), radiation therapy and chemotherapy.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-06-02.
Collapse
|
55
|
Anfossi S, Burks JK, Giordano A, Cohen EN, Gao H, Debeb BG, Woodward W, Ueno NT, Ricardo AH, Hortobagyi GN, Valero V, Reuben JM. Abstract P6-12-12: MiR-19a released by the triple negative inflammatory breast cancer SUM149 cells can be taken up by dendritic cells and induce increased synthesis of the proinflammatory cytokines IL-6 and TNF-a. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p6-12-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Inflammatory breast cancer (IBC) is a rare but highly aggressive form of breast cancer, responsible for 8%–10% of breast cancer–related deaths. To date, a unique molecular signature for IBC able to explain the dramatic differences in survival and tumor aggressiveness compared with non-IBC has not been identified. Triple-negative (TN) subtype is associated with worse clinical outcome in IBC patients. Tumor-associated dendritic cells (DCs) are the central regulators of immune responses in the tumor microenvironment, where the crosstalk with IBC cells may induce proinflammatory immune responses responsible of the development of highly aggressive tumor cells: cancer stem cells with epithelial mesenchymal transition (CSCs/EMT) phenotype. The two miR-19a target genes PTEN and SOCS1 regulate DC activation and maturation by inhibiting toll-like receptor (TLR) and CD40 signaling. As we found that the TN-IBC SUM149 cells expressed and secreted higher levels of miR-19a compared with the TN non-IBC SUM159 cells, we hypothesized that miR-19a secreted by SUM149 cells can be taken up by DCs and downregulate PTEN and SOCS1, leading to increased maturation of DC and production of proinflammatory cytokines upon TLR-mediated activation.
Methods: DCs were generated from healthy donor-derived monocytes cultured for 5 days in RPMI 10% FBS supplemented with IL-4 and GM-CSF 1000 U/ml. To track miRNA transfer to DCs, SUM149 cells were transfected with either Dy547-labeled non-targeting miRNA or miR-19a-mimic, then co-cultured with DCs in 1.0 mm pore size transwell chambers for 24 h. MiRNA uptake by DCs was assessed by confocal fluorescence microscopy and qRT-PCR. The effect of miR-19a uptake by DCs were assessed by measuring: the levels of PTEN and SOCS1 mRNA after 24 h of DC co-culture with miR-19a-transfected SUM149; the expression levels of the costimulatory-activation markers CD80, CD86, CD40, CD83, HLA-DR (by FACS); and the production of IL-6, TNF-α (by ELISA) after DC activation by TLR4/LPS (100 ng for 18 h). As IL-6 induces STAT3, a transcription factor for miR-19a, we also evaluated the effect of IL-6 on miR-19a expression in SUM149 cells.
Results: Fluorescent Dy547-labeled miRNA and miR-19a were transferred from SUM149 to DCs. The uptake of miR-19a induced the downregulation of both PTEN and SOCS1 mRNA in DCs, leading to increased expression of costimulatory-activation markers and production of IL-6 and TNF-α after DC activation by TLR4/LPS vs control. Stimulation of SUM149 cells with IL-6 upregulated miR-19a expression that was associated with an increased expression of CSC markers (CD44+CD24−Aldefluor+) and upregulation of EMT-regulating transcription factors.
Conclusion: DCs can uptake miR-19a secreted by SUM149 cells, leading to increased production of IL-6 and TNF-α upon DC activation by TLR stimulation. IL-6 upregulated miR-19a expression in SUM149 cells. Therefore, miR-19a/IL-6 self-sustaining loop may represent a novel way by which TN-IBC cells maintain a proinflammatory tumor microenvironment able to induce the development of tumor cells with CSCs/EMT phenotype responsible of the poor prognosis of patients with TN-IBC.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-12-12.
Collapse
|
56
|
Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Arun B, Chavez-Macgregor M, Alvarez RH, Lucci A, Krishnamurthy S, Hortobagyi GN, Valero V, Ueno NT. Abstract P6-12-02: Survival differences between patients with metastatic inflammatory and non-inflammatory breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p6-12-02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Very little is known about the survival of patients with inflammatory breast cancer (IBC) and distant metastasis. Furthermore, the American Joint Committee on Cancer classification of breast cancer does not recognize metastatic IBC as a distinct entity within stage IV. We hypothesized that the survival of patients with IBC and distant metastasis is worse than the survival of patients with stage-matched non-IBC.
Patients and Methods: We retrospectively reviewed 5314 consecutive patients with stage III or IV breast cancer (IBC or non-IBC) who were treated at our institution between 1986 and 2012. A total of 1079 patients presented with IBC (stage III: 861; stage IV: 218) and 4235 non-IBC (stage III: 2781; stage IV: 1454). We compared the time to distant metastasis from initial diagnosis, distant metastasis–free survival (DMFS), and overall survival (OS) in stage-matched patients with IBC or non-IBC.
Results: The median follow-up periods were 3.3 years for patients with stage III disease (range, 0-32.2 years) and 1.8 years for patients with stage IV disease (range, 0-19.9 years). The total number of recorded events (metastasis/death) was 1657 for stage III, while the numbers of deaths for stage III and IV were 1337 and 973, respectively. In patients with stage III, the time to distant metastasis was shorter in IBC than in non-IBC (median 1.3 vs. 1.7 years, P < .001). DMFS and OS were shorter in patients with stage III IBC than in those with stage III non-IBC (2.5 vs. 6.9 years, P < .001; and 4.7 vs. 8.9 years, P < .001; respectively). However, there was no significant difference in OS after development of distant metastasis between stage III IBC and non-IBC (median for both 1.3 years, P = .83). In multivariate analysis, the diagnosis of IBC remained significantly associated with mortality after adjusting for potential confounders. De novo stage IV IBC presented more frequently with multiple sites of metastasis than de novo stage IV non-IBC (P = .02). In patients with de novo stage IV disease, OS was shorter in IBC than in non-IBC (2.3 vs. 3.4 years, P = .004). In the multicovariate Cox model, while ethnicity, tumor grade, hormone receptor status and HER2 status, site of metastasis, number of sites of metastasis, and definitive breast surgery by 1 year were all significant factors in OS for stage IV breast cancer, the diagnosis of IBC conferred a hazard ratio of 1.33 (95% confidence interval: 1.05 - 1.69) in multivariate analysis.
Conclusion: Our findings suggest that IBC patients with metastasis at diagnosis have worse outcomes than stage-matched non-IBC patients. IBC patients presenting with de novo stage IV disease should be considered as a separate subcategory of stage IV in the tumor-node-metastasis classification because their clinical course and prognosis are different from those of patients with stage IV non-IBC.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-12-02.
Collapse
|
57
|
Kai K, Kondo K, Bartholomeusz C, Valero V, Hortobagyi GN, Ueno NT. Abstract P2-09-04: Development of novel combination therapy of IGF-1R/InsR and MEK inhibitors in triple-negative breast cancer (TNBC). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p2-09-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Recent studies found that TNBC had a highly activated profile in the insulin-like growth factor 1 receptor (IGF-1R)/insulin receptor (InsR) pathway. Patients in whom the IGF-1R/InsR pathway was activated had a worse prognosis than did those in whom the pathway was not activated. We also previously found that the tumor-initiating cells in mouse TNBCs had a highly activated IGF-1R pathway. On the basis of these findings, we tested an IGF-1R/InsR dual kinase inhibitor, KW-2450, in TNBC. Results: To investigate the antitumor effects of KW-2450 in TNBC, we first confirmed the high IGF-1R and low InsR expression in TNBC cell lines (e.g., SUM149, MDA-MB-231, MDA-MB-468). An in vitro growth inhibition assay revealed that KW-2450 inhibited cell growth (all IC50 <0.5 μM), and an agar assay for colony formation confirmed this antitumor effect in TNBC cells. We also tested KW-2450's inhibitory effect against cancer stem cell (CSC) activity. With KW-2450 treatment of SUM149 and MDA-MB-231 cells, proportions of CSCs, profiled as CD44+CD24−, were significantly reduced in a dose-dependent manner. Indeed, KW-2450 dose-dependently inhibited mammosphere-forming, a hallmark of CSC activity. Cell cycle analysis revealed that KW-2450 induced mitotic accumulation and apoptosis in TNBC cells. Interestingly, MDA-MB-468 cells were the most susceptible to death, and their sensitivity to KW-2450 was associated with the high activation level of the mitotic checkpoint, the levels of which were determined by accumulation of cyclin B1 (on Western blot) and of phospho-histone H3–positive cells, a mitosis marker (on FACS). In contrast, SUM149 and MDA-MB-231 cells, which are relatively unsusceptible to death from KW-2450, exited from mitosis (as indicated by an accumulation of 8N; octaploidy) without significant cell death. This variable sensitivity to KW-2450 was also observed in in vivo studies. We confirmed that MDA-MB-468 tumors that were treated with 80 mg/kg of KW-2450 in vivo were stable and had many more mitotic cells than did those treated with vehicle control, which suggests that mitotic accumulation is a key process for this antitumor effect. Since it is known that any of the MAPKs (e.g., JNKs, p38 kinase, ERKs) become activated at the mitotic phase in mammalian cells, we next investigated whether the activation levels of MAPKs play critical roles in either mitotic progression or mitotic death in TNBC. Western blot analysis revealed that KW-2450 activated ERKs, but not JNKs or p38 kinase, in KW-2450–insensitive MDA-MB-231 and SUM149 cells, suggesting that ERK activation may promote mitotic progression but not mitotic death. Indeed, the combination of a MEK inhibitor (AZD6244), which inhibits ERK activation, and KW-2450 significantly reduced the 8N fraction and increased cell death in SUM149 and MDA-MB-231 cells. Conclusion: KW-2450 had significant antitumor effects in vitro and in vivo in TNBC cells. KW-2450–induced cell death, accompanied by mitotic accumulation, depended on mitotic checkpoint activity. TNBC cells refractory to KW-2450 were sensitized to KW-2450 by the addition of a MEK inhibitor. This novel combination therapy targeting IGF-1R/InsR and MEK in TNBCs, whose mitotic checkpoints are commonly abrogated, needs to be developed.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-09-04.
Collapse
|
58
|
Woodward WA, Arriaga L, Gao H, Cohen EN, Li L, Reuben JM, Munsell MF, Valero V, Le-Petross H, Melhem-Betrandt A, Moulder S, Middleton LP, Strom EA, Tereffe W, Hoffman K, Smith BD, Buchholz TA, Perkins GH. Abstract P5-14-08: Prospective phase II study of concurrent capecitabine and radiation demonstrates futility in triple negative chemo-resistant breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-14-08] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Capecitabine is an established radiosensitizer in rectal and other cancers. We conducted a prospective single arm phase II study to examine the response rate of gross chemo-refractory breast cancer treated with concurrent capecitabine and radiotherapy.
Methods: Patients who had inoperable or marginally operable gross disease in the breast and/or lymph node(s) after chemotherapy or gross disease on the chest wall or in the regional lymphatics after mastectomy were eligible. Patients 1-9 received capecitabine 825 mg/m2 BID daily beginning on the first day of radiotherapy. Excess grade 3 toxicity (%) was observed; the protocol was amended and subsequent patients received drug only on radiation treatment days. Radiation dose was at the discretion of the treating physician (50Gy-72 Gy, with no more than 2.5 Gy/fraction). Response was assessed by a single physician using paired radiation planning CTs (pretreatment and on-treatment after 45 Gy). Clinical correlation to all other available imaging was also made. Kaplan-Meier curves were used to estimate overall survival (OS) and local recurrence-free survival (LRFS). Circulating tumor cells (CTCs) in blood were examined in consenting patients.
Results: The trial was stopped early after an unplanned interim analysis prompted by slow accrual suggested futility independent of response. From 2009-2012, 32 patients were accrued; 26 completed protocol specific treatment (17 post-mastectomy radiation with gross nodes, 4 pre-op, 5 aggressive palliation) and are included in this analysis. Median follow up was 7.3 months (interquartile range 6.7 – 17.4). Nineteen patients (73%) had a partial or complete response. Fourteen patients (53.9%) experienced at least one grade 3 non-dermatitis toxicity including 7/9 treated with continuous dosing. Four inoperable patients were treated with pre-op radiation therapy and 3 converted to operable. None achieved a pCR or near pCR. One-year actuarial OS was 52%. There was no difference in OS comparing among PMRT vs. preoperative or palliative RT (P = 0.90). One-year actuarial local recurrence free survival among PMRT patients was 38%. Ten patients had triple negative (TN) receptor status. There was no difference in radiation response by receptor status (P = 0.56); however, treatment was deemed subjectively futile (i.e., converted to operable but death secondary to new widespread M1 disease immediately post-op) in 9 of the 10 patients with TN disease versus 6 of the 16 patients with non-TN disease (P = 0.014). Median OS and 1-yr actuarial OS, among non-TN vs. TN patients were not reached vs. 6.1 months and 77% vs. 10% (P < 0.001), respectively. Eight/fifteen patients tested were positive for CTCs. CTCs did not correlate to receptor status, futility of RT or OS.
Conclusions: Capecitabine can be safely administered as a daily concurrent chemoradiation regimen with weekend holidays. However, in this small, prospective and selected cohort, concurrent chemoradiation with capecitabine was futile among patients with TN breast cancer. Alternative strategies are urgently needed in TN patients.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-14-08.
Collapse
|
59
|
Lee BN, Arun BK, Cohen EN, Tin S, Gutierrez-Barrera AM, Miura T, Kiyokawa I, Alvarez RH, Valero V, Ueno NT, Cristofanilli M, Reuben JM. Abstract P2-10-32: Sialyl LewisX and inflammatory mediators in breast cancer patients: biological correlations and prognostic value. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-10-32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Cytokines and chemokines are known to be involved in tumor growth and progression of disease. Sialyl LewisX (sLeX), a ligand for adhesion molecule E-selectin, is known to affect inflammatory processes and an elevated level is associated with tumor metastasis. Therefore, we assessed serum levels of sLeX and cytokines/chemokines in patients with non-invasive ductal carcinoma in situ (DCIS), early invasive breast cancer (EBC), or metastatic breast cancer (MBC).
Patients and Methods: Sera from 250 patients (26 DCIS, 157 EBC, 67 MBC) and 43 healthy donors (HD) were assayed for sLeX using an immunoassay kit (CSLEX; Nittobo Medical Co. Ltd., Japan) and a panel of cytokines and chemokines using a multiplex assay kit. Differences in serum markers between patients and HD, and among patient groups were determined using the Kruskal-Wallis and Mann-Whitney tests. Spearman's correlation determined the non-parametric correlation between the serum levels of sLeX and the inflammatory mediators. The receiver operating characteristic (ROC) curves and the corresponding area under the curve (AUC) analyses were used to determine the sensitivity and specificity of a given cut-off value for a particular serum marker.
Results: The median sLeX level tended to increase with the stage of disease: MBC > EBC > DCIS albeit without significant differences among the disease stages. Among MBC patients, patients with sLeX below 1.75 U/mL had significantly improved overall survival (OS, mean survival 11.1 vs. 33.7 months, P = 0.002) and progression-free survival (PFS, mean survival 9.7 vs. 20.9 months, p = 0.042). The Hazard Ratio of high sLeX for OS was 5.5 (95% CI 1.6 to 18.9, p = 0.007) and 2.3 for PFS (95% CI 1.0 to 5.2, P = 0.048). EBC and MBC patients have significantly higher serum levels of IL-1, IL-1RA, IL-6, IL-8, MCP-1, MCP-3, and MIP-1βthan those of HD. In addition, there were positive correlations between the serum levels of sLeX and cytokines IL-1β, IL-1RA, IL-2, IL-8, MIP-1β, and MCP-3. The AUC for sLeX was 0.598 (P = 0.016), and a cut-off of 3.13 pg/mL distinguished hormone receptor (HR)-positive from HR-negative patients (χ2 = 4.0, P = 0.045). Likewise, the AUC for TNF-α was 0.620 (P = 0.003), and a cut-off 7.18 pg/mL distinguished HR-positive from HR-negative patients (χ2 = 12.6, P < 0.001). Using a cut-off value established by ROC curves, few MBC patients (9 of 66, 13.6%) had a serum IL-2 level > 7.1 pg/mL compared to 57 of 185 (30.8%) non-MBC patients (χ2 = 7.4, P = 0.007), suggesting that metastatic disease may be associated with immune suppression related to low serum IL-2. Conversely, 31of 66 (47%) MBC patients had a serum MCP-1 level > 750 pg/mL vs. 37 of 185 non-MBC patients (20%) (χ2 = 23.8, P < 0.0001), suggesting that a high level of MCP-1 may play an important role in metastasis.
Conclusion: Serum levels of sLeX were able to distinguish HR-positive from HR-negative patients and predict overall survival in metastatic patients. Serum sLeX and some inflammatory mediators tended to increase with the severity of disease, and together may facilitate local invasion of tumor cells. Furthermore, serum levels of MCP-1 and IL-2 may have prognostic value in breast cancer patients.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-10-32.
Collapse
|
60
|
Conter HJ, Conter D, Wolff RA, Valero V, Zwelling L. Abstract P5-15-02: The benefit of targeted therapeutics in medical oncology since the development of trastuzumab. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p5-15-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Trastuzumab has achieved widespread approval and funding across much of the developed world for metastatic and, later, adjuvant HER2/neu positive breast cancer. This success may be attributed to a favorable therapeutic index and incremental cost-effectiveness ratio (ICER). Has the success of trastuzumab been replicated by newer therapeutics?
Methods: The societal marginal benefit gained from a new drug can be estimated by calculating the difference between the incremental quality-adjusted life-years gained (QALY) and the maximum willingness-to-pay (WTP) for the increase in health by society. A systematic review was employed to amass all English-language cost-effectiveness analyses (CEA) on small-molecule inhibitors and monoclonal antibodies approved for the treatment of solid malignancies. Searches of PubMed and EMBASE provided citations published between 1995 and February 5, 2012. Two reviewers each independently assessed the eligibility of all abstracts and subsequently abstracted data from published abstracts and manuscripts. CEAs comparing two experimental treatments to each other were excluded. Incremental costs and ICERs were converted from their native currency to U.S. dollars according to their average exchange-rates since publication.
Results: Of the 1,576 citations identified, 60 were included in the final analysis. Tumor-types studied included breast, colorectal, gastric, gastrointestinal stromal, head and neck, non-small cell lung, ovarian, hepatocellular, and renal cancers, and pancreatic neuro-endocrine tumor. Studies originated from USA (14%), continental Europe (37%), England (12%), Canada (12%), Asia (11%), and Latin America (12%). Median WTP was $65,000 (range $30,000-$297,000). 92% of all CEAs included considered to be cost-effective by the CEA's authors. Trastuzumab was studied for breast cancer treatment by 13 CEAs in the adjuvant setting and by 3 CEAs in the metastatic setting. Trastuzumab is significantly more cost-effective than other targeted treatments (mean ICER $32,000 vs. $108,000, p = 0.001). 84% of trastuzumab studies found its ICER<$40,000, but only 32% of other CEAs met this threshold. Trastuzumab may be more cost-effective if employed in the adjuvant setting compared to the metastatic setting (mean ICER $18,000 vs. $29,000, p = 0.12). After trastuzumab, the most favorable treatments by ICER were imatinib for GIST, cetuximab with radiation for head and neck cancer, and sorafenib for hepatocellular carcinoma. There was no apparent relationship between the country of origin in which the CEA was conducted and the ICER estimate.
Conclusion: Trastuzumab represents a significant achievement in clinical medicine and also provides greater value than newer targeted chemotherapy, in general. Newer therapeutics are being priced close to the maximum WTP of society. Adjuvant therapy may prove more cost-effective than therapy in the metastatic setting. Unless better pricing arrangements can be made or future therapies produce greater incremental clinical benefits for the same cost, it seems unlikely that the societal success of trastuzumab will be replicated. However, this analysis assumes that maximizing societal health, not profit, is of primary concern.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-15-02.
Collapse
|
61
|
Masuda H, Iwamoto T, Brewer T, Hsu L, Kai K, Woodward WA, Reuben JM, Valero V, Alvarez RH, Willey J, Hortobagyi GN, Ueno NT. Abstract P3-10-05: Response to neoadjuvant systemic therapy (NST) in inflammatory breast cancer (IBC) according to estrogen receptor (ER) and HER2 expression. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p3-10-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Inflammatory breast cancer (IBC) is the most aggressive form breast cancer. NST, followed by local therapy (surgery and radiation therapy), is considered the current standard therapy for IBC. Among noninflammatory breast cancers, sensitivity to NST differs based on ER and HER2 status. However, whether the sensitivity to NST also differs in primary IBC based on ER status or other prognostic factors has not been studied in a large cohort.
Methods: We retrospectively reviewed 1078 patients (pts) newly diagnosed with IBC from April 1989 to January 2011. Of these, 838 pts met our inclusion criterion of stage III disease at diagnosis, and 713 of these pts had received NST and surgery. Among this population, 545 pts had information available on both ER and HER2 status. We compared pathological complete response (pCR) rates (defined as no evidence of invasive disease in the breast and ipsilateral axillary limph nodes) and clinical characteristics between ER and HER2-status subgroups and analyzed their clinical outcome. We used the Kaplan-Meier method to estimate the median recurrence-free survival (RFS) after surgery and overall survival (OS), and the Cox proportional hazards regression model to test the statistical significance of potential prognostic factors in each group.
Results: Overall 177 pts had ER+HER2− tumors; 75, ER+HER2+; 134, ER-HER2+; and 159, ER-HER2−. NST consisted of anthracycline-based [A] alone, a taxane [T] alone or with A+T; HER2 targeting therapies (H) were administered to 117 patients with HER2-positive breast cancer after 1998. Overall pCR rate was 14.7%. pCR rates are shown by marker subtype and NST received in the table below. pCR rate, nuclear grade, vascular invasion, clinical response to NST, adjuvant treatment, radiation therapy, and adjuvant hormonal therapy differed significantly among subgroups.
The median RFS and OS for all patients was 19.2 and 33.2 months, respectively. In multivariate analysis, BMI, ER status, lymphatic invasion, radiation therapy, and pCR rate were associated with RFS, and ER status, vascular invasion, radiation therapy, and pCR rate were associated with OS. Except in the ER+HER2− group, pCR was associated with better prognosis compared to non-pCR. Adjuvant hormonal therapy improved RFS both in ER+HER2+ and ER+HER2− groups, but did not improve OS in the ER+HER2+ group. Among 209 patients with HER2+ IBC, 134 received HER2 targeting therapies in neoadjuvant or adjuvant chemotherapy, and had a trend to improvement in RFS compared to chemotherapy alone (p = 0.082). The ER-HER2− group showed poorest outcome compared to other subgroups (P < 0.001).
Conclusions: Sensitivity to NST differs depending on the ER and HER2 status in IBC pts. pCR rates based on these subgroups appear to be low. There is a need more effective treatments in the neoadjuvant and adjuvant therapies for all subgroups of IBC.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-10-05.
Collapse
|
62
|
Ueno NT, Jackson SA, Alvarez RH, Willey JS, Hortobagyi GN, Angulo-Gonzalez AM, Giordano SH, Booser DJ, Valero V. Abstract P5-20-13: Preliminary report of a phase I/II study of entinostat (IND#NSC 706995, /M275) and lapatinib (IND#NSC 727989) in patients with HER2-positive metastatic breast cancer in whom trastuzumab has failed. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p5-20-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Entinostat is a novel, potent, orally bioavailable, class I selective histone deacetylase inhibitor. Pre-clinical data has shown that Entinostat can enhance the activity of Lapatinib in HER2+ metastatic inflammatory and non-inflammatory breast cancer. The primary objective of the phase I portion of this study is to determine the recommended phase II dose for Entinostat in combination with Lapatinib in patients who have received Trastuzumab for HER2+ metastatic breast cancer.
Methods: This is a single center, open-label study to evaluate the safety and tolerability of every other week entinostat in combination with a 28-day cycle of Lapatinib. Patients with metastatic breast cancer in whom trastuzumab has failed were included. The phase I portion of the study is a conventional 3+3 dose-escalation design. Dose levels include 0 (starting dose) Entinostat 10 mg orally every other week, I Entinostat 12 mg, and II Entinostat 15 mg. Lapatinib 1,250 mg orally is given every day without dose escalation. Toxicities are evaluated at the end of each cycle.
Results: Here we report the phase I portion of the study. To date, 9 patients were enrolled, 3 were in level 0, and 6 were in level I. In Level 0, 2 patients were taken off study due to disease progression (PD) at the end of cycle one and 1 patient was taken off study due to PD at the end of cycle two. In Level I, 1 patient was taken off study due to PD at the end of cycle one and 2 patients were taken off study due to PD at the end of cycle 2. 1 patient had stable disease. The median age is 41 (range, 26–69). Seven of the nine patients are evaluable for toxicity. Most common toxicities reported by the patients are nausea grade 3 (1), fatigue grade 3 (1), muscle aches/pain grade 2 (3), skin rash grade 3 (1), paresthesias grade 2 (2), heartburn grade 1 (4), and diarrhea Grade 2 (1). Lapatinib dose was reduced in 2 patients. The most common hematological toxicities were neutropenia grade 1 (3), anemia grade 2 (1), and thrombocytopenia grade 4 (1).
Conclusions: Overall, patients have tolerated the combination regimen relatively well. We have not reached the maximum tolerated dose, so patient enrollment will continue until the phase I portion of the study is complete, most likely in July 2012. We plan to proceed with phase II portion in two parallel cohorts (HER2+ inflammatory and non-inflammatory metastatic breast cancer).
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-20-13.
Collapse
|
63
|
Willey JS, Alvarez RH, Valero V, Lara JM, Parker CA, Hortobagyi GN, Ueno NT. Abstract OT2-3-10: Phase II study of panitumumab, nab-paclitaxel, and carboplatin for patients with primary inflammatory breast cancer (IBC) without HER2 overexpression. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-ot2-3-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Inflammatory breast cancer (IBC) is the most aggressive form of primary breast cancer. The outcome for patients with IBC is bleak despite multimodality treatment approaches. 10-year disease-free survival rates after combined anthracycline and taxane-containing chemotherapy, surgery, and radiation are only 20%–25%. Our recent study found EGFR overexpression, a predictive factor of poor outcome, in 12 of 40 (30%) patients with IBC. Panitumumab has shown activity against EGFR overexpressing breast cancer xenograft model.
Trial design: This is a single center, open-label, phase II study to evaluate the safety and efficacy of panitumumab in combination with preoperative chemotherapy. The treatment regimen consists panitumumab 2.5 mg/Kg given intravenously alone for the first week, followed by weekly panitumumab, nab-paclitaxel (100mg/m2) and carboplatin (2 AUC) (PNC) for 12 weeks. Patients then will receive 5-FU, epirubicin, and cyclophosphamide (FEC) every 3 weeks for 4 cycles prior to surgery.
Eligibility criteria: 1) Histological confirmation of breast carcinoma with pathologic evidence of dermal lymphatic invasion and clinical diagnosis of IBC, including diffuse erythema, heat, ridging, and peau d'orange; 2) Normal HER2 expression; 3) No prior therapies for IBC; 4) Adequate hematologic, cardiac, renal and hepatic functions.
Specific aims: 1) Primary objective is to determine the pathologic complete response (pCR) rate in patients with primary IBC without HER2 overexpression; 2) Secondary objectives are to determine the disease-free survival (DFS), overall survival (OS), the safety and tolerability of PNC regimens and the correlates of pathologic response rate and EGFR expression level.
Statistical methods: 1) Previous studies have shown that this IBC patient population achieved a 13% pCR rate on the standard of care. We assume a beta (0.26, 1.74) prior distribution for the pCR rate. This prior distribution has a mean of 13% and a standard deviation of 19%. 2) We will stop the trial early if P (pCR rate >/= 13%) is < 0.01. If we determine that there is less than a 1% chance that the pCR rate is 13% or more we will consider stopping the trial. 3) Once we have completed the study we will estimate the pCR rate with a 90% credible interval. If we have pCR in 4 of the 40 patients (10%), then our 90% credible interval for the pCR rate will be 4.0–19.6%. If we have pCR in 8 of the 40 patients (20%), then our 90% credible interval for the pCR rate will be 10.6–30.4%. We will also report the posterior probability that the pCR rate is 13% or more. For example, if we have pCR in 8 of the 40 patients (20%), then the probability that the pCR rate is 13% or more is 0.869.
Present accrual and target accrual: To date, 13 patients have been enrolled. Target accrual is 40 patients.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr OT2-3-10.
Collapse
|
64
|
Chavez MGM, Lei X, Giordano SH, Valero V, Esteva F, Mittendorf EA, Gonzalez-Angulo AM, Hortobagyi GN. Abstract P5-20-02: Predictors of long-term survival in a large cohort of patients with HER2-positive (HER2+) metastatic breast cancer (MBC). Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p5-20-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Numerous studies have examined prognostic factors for survival in breast cancer patients (pts), but few have focused on long-term survival among pts with HER2+ MBC receiving HER2-targeted therapy. In this study we sought to evaluate the clinical characteristics and predictive factors of long-term survival in this group of pts.
Methods: All pts with HER2+ MBC treated with HER2-directed therapy at MD Anderson Cancer Center were identified by retrospective review of the Institutional Breast Medical Oncology database. HER2 status was determined by IHC or FISH. Patient characteristics were analyzed using descriptive statistics. Overall survival (OS) was measured from the date of diagnosis of the first distant metastasis to the date of death or last contact. Pts were grouped according to OS and categorized as long term-survivors (LTS, OS ≥5 years), or non-long term survivors (non-LTS, OS <5 years). A multivariable logistic regression model was fit to examine the relationship between long-term survival and patient characteristics.
Results: We identified 1603 pts diagnosed with HER2+ MBC between 1994 and 2012 and treated with HER2-targeted therapy. A total of 154 (14.5%) pts were categorized as LTS (median follow-up 80 months, median OS 92.2 months); in this subgroup we identified 10 pts that survived ≥10 years. There were 909 (85.5%) not-LTS (median follow-up 20 months, median OS 27.6 months). Among LTS, 67.5% of the pts were younger than 50 years old; 63.4% had HR-positive tumors and initial stage at the time of diagnosis was I in 11.9%, II in 39.9%, III in 16.3% and stage IV de novo in 32% of the pts. 5-year survival estimates demonstrated differences according to age (31% in patients ≤50 years vs. 25% in patients >50, p = 0.005); stage at diagnosis (25% for stage I-III vs. 36% for stage IV de novo, p < 0.001); HR status (35% in HR-positive vs. 22% in HR-negative, p < 0.001) and number of sites of metastatic disease (33%, 25% and 19% for 1, 2 and ≥3 sites, p < 0.001). By multivariable analysis, we identified that HR-positivity (OR = 1.69; 95% CI 1.17–2.44), number of sites of metastases (3 vs. 1 OR = 0.41; 95% CI 0.23–0.72), location of metastases (visceral vs. bone-soft tissue OR = 0.61; 95% CI 0.4–0.91), resection of metastases (OR = 2.38; 95% CI 1.53–3.69) and primary breast surgery among pts with stage IV de novo (OR = 2.88; 95% CI 1.47–5.66) were significantly associated with long-term survival.
Conclusions: Some patients with HER2+positive MBC have an excellent outcome, particularly younger pts with HR-positive tumors, low burden of disease and non-visceral metastases in which multidisciplinary treatment is favored. In the era of HER2-targeted therapies, 14.5% of the patients are long-term survivors. To our knowledge this is the largest series identifying the characteristics of this group of patients.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-20-02.
Collapse
|
65
|
Lynch SP, Lei X, Chavez-MacGregor M, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang A, Hortobagyi GN, Valero V, Gonzalez-Angulo AM. Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol 2012; 23:3063-3069. [PMID: 22776706 PMCID: PMC3501230 DOI: 10.1093/annonc/mds136] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2012] [Revised: 03/22/2012] [Accepted: 03/27/2012] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND The clinicopathological characteristics and the prognostic significance of multifocal (MF) and multicentric (MC) breast cancers are not well established. PATIENTS AND METHODS MF and MC were defined as more than one lesion in the same quadrant or in separate quadrants, respectively. The Kaplan-Meier product limit was used to calculate recurrence-free survival (RFS), breast cancer-specific survival (BCSS), and overall survival (OS). Cox proportional hazards models were fit to determine independent associations of MF/MC disease with survival outcomes. RESULTS Of 3924 patients, 942 (24%) had MF (n = 695) or MC (n = 247) disease. MF/MC disease was associated with higher T stages (T2: 26% versus 21.6%; T3: 7.4% versus 2.3%, P < 0.001), grade 3 disease (44% versus 38.2%, P < 0.001), lymphovascular invasion (26.2% versus 19.3%, P < 0.001), and lymph node metastases (43.1% versus 27.3%, P < 0.001). MC, but not MF, breast cancers were associated with a worse 5-year RFS (90% versus 95%, P = 0.02) and BCSS (95% versus 97%, P = 0.01). Multivariate analysis shows that MF or MC did not have an independent impact on RFS, BCSS, or OS. CONCLUSIONS MF/MC breast cancers were associated with poor prognostic factors, but were not independent predictors of worse survival outcomes. Our findings support the current TNM staging system of using the diameter of the largest lesion to assign T stage.
Collapse
|
66
|
Woodward W, Huo L, Li J, Sneige N, Gonzalez-Angulo A, Debeb B, Chang C, Hung M, Valero V, Ueno N. EZH2 Expression Correlates With Locoregional Recurrence After Radiation in Inflammatory Breast Cancer. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
67
|
Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 2012; 23:1144-1150. [PMID: 21965473 DOI: 10.1093/annonc/mdr434] [Citation(s) in RCA: 91] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND Circulating tumor cells (CTCs) are associated with inferior prognosis in metastatic breast cancer (MBC). We hypothesized that the relationship between CTCs and disease subtype would provide a better understanding of the clinical and biologic behavior of MBC. PATIENTS AND METHODS We retrospectively analyzed 517 MBC patients treated at a single institution. Subtypes of primary tumors were analyzed by immunohistochemical (IHC) or fluorescent in situ hybridization analyses and CTCs were enumerated by CellSearch(®) at starting a new therapy. Overall survival (OS) and progression-free survival durations for each IHC subtype were determined. RESULTS At a median follow-up of 24.6 months, 276 of 517 (53%) patients had died. The median OS for patients with <5 and ≥ 5 CTCs were 32.4 and 18.3 months, respectively (P < 0.001). Except in HER2+ patients, the prognostic value of CTCs was independent of disease subtype and disease site. CONCLUSIONS In this large retrospective study, CTCs were strongly predictive of survival in all MBC subtypes except HER2+ patients who had been treated with targeted therapy. Our results clearly demonstrate the value of enumerating CTCs in MBC and strongly suggest an interesting biological implication in the HER2+ subset of patients that need to be further explored.
Collapse
|
68
|
Lester TR, Hunt KK, Nayeemuddin KM, Bassett RL, Gonzalez-Angulo AM, Feig BW, Huo L, Rourke LL, Davis WG, Valero V, Gilcrease MZ. Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res Treat 2012; 131:41-8. [PMID: 21331622 PMCID: PMC3867807 DOI: 10.1007/s10549-011-1393-6] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2010] [Accepted: 02/02/2011] [Indexed: 12/26/2022]
Abstract
Metaplastic sarcomatoid carcinoma (MSC) of the breast is usually triple receptor (ER, PR, and HER2) negative and is not currently recognized as being more aggressive than other triple receptor-negative breast cancers. We reviewed archival tissue sections from surgical resection specimens of 47 patients with MSC of the breast and evaluated the association between various clinicopathologic features and patient survival. We also evaluated the clinical outcome of MSC patients compared to a control group of patients with triple receptor-negative invasive breast carcinoma matched for patient age, clinical stage, tumor grade, treatment with chemotherapy, and treatment with radiation therapy. Factors independently associated with decreased disease-free survival among patients with stage I-III MSC of the breast were patient age > 50 years (P = 0.029) and the presence of nodal macrometastases (P = 0.003). In early-stage (stage I-II) MSC, decreased disease-free survival was observed for patients with a sarcomatoid component comprising ≥ 95% of the tumor (P = 0.032), but tumor size was the only independent adverse prognostic factor in early-stage patients (P = 0.043). Compared to a control group of triple receptor-negative patients, patients with stage I-III MSC had decreased disease-free survival (two-sided log rank, P = 0.018). Five-year disease-free survival was 44 ± 8% versus 74 ± 7% for patients with MSC versus triple receptor-negative breast cancer, respectively. We conclude that MSC of the breast appears more aggressive than other triple receptor-negative breast cancers.
Collapse
|
69
|
Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. P1-07-09: Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1%-10% ER-Positive by Immunohistochemistry. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p1-07-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: Our goal was to examine whether borderline estrogen receptor (ER)-positive cancers, defined as 1–10% positivity by immunohistochemistry (IHC), show the same global gene expression pattern and high ESR1 mRNA expression as ER-positive cancers or are more similar to ER-negative cancers.
Patients and methods: ER status was determined by IHC in 465 primary breast cancers and with Affymetrix U133A gene chip (ESR1 mRNA gene expression: Probe set = 205225_at). We compared expressions of ESR1 mRNA and a 106-probe set ER-associated gene signature score between ER-negative (n=183), 1–9% (n=25), exactly 10% (n=6), and > 10% ER-positive (n=251) cancers. We also assessed the molecular class of the borderline ER-positive cases using the PAM-50 classifier.
Results: Among the 1–9%, 10% and > 10% IHC positive cases, 24%, 67% and 92% were also ER-positive by ESR1 mRNA expression. The average ESR1 expression was significantly higher in the > 10% IHC-positive cohorts compared to the 1–9% or completely negative cases but in these latter two cohorts ER expression was similarly low. The average ER gene signature scores were similar for the ER-negative and 1–9% IHC-positive cases, but significantly lower than in > 10% ER-positive cases. None of the 1–9% ER-positive cases were classified as Luminal A, 2 were Luminal B and 12 were Basal-like. Among the 10% ER-positive cases, 2 were Luminal A and 1 was Luminal B. Conclusion: Overall, 24% of the 1–9% and 67% of the 10% ER-positive cancers show ESR1 mRNA levels and gene signatures that are consistent with ER-positive, potentially endocrine sensitive tumors.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-07-09.
Collapse
|
70
|
Gao H, Cohen EN, Lee BN, Giordano A, Tin S, Anfossi S, Parker CA, Cristofanilli M, Valero V, Alvarez RH, Hortobagyi GN, Woodward WA, Ueno NT, Reuben JM. P4-20-04: Cytokine Synthesis by Activated Dendritic Cells in Relation to Disease Progression in Inflammatory Breast Cancer (IBC). Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-20-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Deficiencies in innate and adaptive immune responses by plasmacytoid dendritic cells (pDC) and myeloid DC (mDC) have been linked to poor clinical outcome in breast cancer (BC) (Treilleux, Clin Cancer Res, 2004, PMID 15569976). pDC produce IFN-a and pro-inflammatory cytokines that regulate innate and adaptive immunity in breast cancer. mDC present in blood and secondary lymphoid organs secrete IL-12 and induce inflammatory cytokine production by T cells. Therefore, we studied DC activity in the peripheral blood and assessed their function with clinical outcome in breast cancer patients.
Methods: We recruited 115 BC patients [25 with locally advanced non-IBC (LABC), 25 with IBC, 21 with metastatic breast cancer (MBC), and 44 with metastatic IBC (mIBC)] and 31 healthy donors (HD) for this study. Peripheral blood pDC and mDC were activated through toll-like receptor (TLR)-7 to assess IFN-α and IL-10 production whereas mDC were activated through TLR-8 to assess production of IL-12 and TNF-α by multi-parameter flow cytometry. Associations between cytokine production by TLR-activated pDC and mDC with progression free survival (PFS) and overall survival (OS) of patients were analyzed by Kaplan Meier Test.
Results: The median follow-up (FU) of 113 evaluable patients was 14.1 months with a median time to progression of 10.5 months; 54 patients had stable disease (SD) and 59 had progression of disease (PD). Metastasis, previous treatments, and IBC contributed to shorter PFS and OS. Compared to HD, BC patients had significantly fewer total DC (p=0.008), mDC (p=0.008), and pDC (p=0.003) per μL. In general, the number of TLR-7-activated pDC per μL that produced IFN-a(p=0.023) or IL-10 (p=0.027) and the number of TLR-8-activated mDC per μL that produced IL-12 (p<0.001) or TNF-α (p=0,008) were significantly lower in BC patients than in HD. However, patients with DC that produced these cytokines above the median levels of HD had shorter PFS or OS. In IBC patients, higher numbers of TLR-8-activated mDC that produced TNF-α (p=0.025) or IL-12 (p=0.003) predicted shorter OS. In mIBC patients, a higher number of TLR-7-activated pDC producing IFN-α (p=0.024) or IL-10 (p=0.034) predicted shorter PFS.
Conclusion: BC patients had significantly fewer pDC and mDC in peripheral blood than HD. IBC patients with above average numbers of TLR-activated DC capable of producing proinflammatory cytokines had a significantly shorter PFS or OS. Disease progression in IBC is related to an increased number of activated dendritic cells producing inflammatory cytokines.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-20-04.
Collapse
|
71
|
Muse KI, Elsayegh N, Gutierrez-Barrera AM, Kuerer H, Valero V, Litton JK, Hortobagyi GN, Arun BK. P4-10-06: Evaluation of BRCAPro Risk Assessment Model in Patients with Ductal Carcinoma In Situ. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-10-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The BRCAPRo model is used to predict a patient's likelihood to possess a BRCA1 or BRCA2 gene mutation based upon personal and family history. Ductal carcinoma in situ (DCIS) is considered a non-invasive condition which can progress to an invasive breast cancer if left untreated. Currently, DCIS is not specifically accounted for in the BRCAPro model, thereby causing DCIS to be weighted in the same manner as an invasive breast cancer diagnosis. Historically, a diagnosis of DCIS has been entered as having developed into an invasive breast cancer ten years later. However, there are no standard guidelines of how DCIS should be entered. We sought to determine if there were any differences in how DCIS was treated in the BRCAPro model to predict the more effective method in calculating the BRCAPro. Methods: Women with pure DCIS, who were referred for genetic counseling and underwent genetic testing, were included in the study. The likelihood of carrying a BRCA mutation was calculated using the BRCAPRO model (Version 5.1). Patient characteristics which were entered into the BRCAPro model include: tumor markers (estrogen receptor-ER and progesterone receptor-PR), history of oophorectomy prior to diagnosis, family history of 1st and 2nd degree relatives with breast and ovarian cancer, race and Ashkenazi Jewish ancestry. Each patient's BRCAPro risk estimate was calculated and compared by entering DCIS at the presenting age of diagnosis and by adding 10 years to the age of diagnosis. Descriptive statistics and a student's t-test were used to compare BRCAPro estimates between the two groups. Results: Ninety-five patients with pure DCIS underwent genetic counseling and testing. The average age of DCIS diagnosis was 45 years (range 26–65). Of the 95 DCIS patients included in the study 21% (n=20) tested positive for a BRCA gene mutation (8 BRCA1 and 12 BRCA2), 77% (n=74) test negative and 0.01% (n=1) had a variant of uncertain significance. Overall, DCIS patients who tested positive for a BRCA mutation had a higher BRCAPro (40%) than patients who tested negative (12%) when presenting age of diagnosis was assessed. When 10 years was added, the BRCAPro estimate was still higher amongst BRCA positive patients (28%) than BRCA negative patients (8%). The mean BRCAPro probability when DCIS was entered at presenting age of diagnosis was 18% (0.1−95.4) versus 12% (0.1−89.9) when calculated 10 years later. Conclusion: In our cohort there was no significant difference in BRCAPro probability whether DCIS was entered at the presenting age of diagnosis or 10 years later (p=0.1). However, future studies are needed to determine the most effective method to incorporate DCIS into the BRCAPro model in order to determine those individuals who may or may not be at increase risk to possess a BRCA gene mutation.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-10-06.
Collapse
|
72
|
Giordano A, Cohen EN, Anfossi S, Gao H, Lee BN, Mego M, Sanda T, Valero V, Alvarez RH, Cristofanilli M, De Placido S, Hortobagyi GN, Woodward W, Ueno NT, Reuben JM. P1-02-07: Epithelial-Mesenchymal Transition Correlated with Serum Cytokine Profiling in Breast Cancer Patients. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p1-02-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Inflammation contributes to the increased invasiveness and poor prognosis in breast cancer (BC) patients. Specifically, the expression of the proinflammatory cytokines interleukin-6 (IL-6), tumor necrosis factor alpha (TNFα) and interleukin-1 (IL-1) have all been linked to increased invasiveness and poor prognosis. Interestingly, the increased invasiveness was associated with an increase in the acquisition of markers of epithelial-mesenchymal transition (EMT). Therefore, we determined whether the levels of circulating proinflammatory cytokines (IL-1, IL-6, TNFα) and antiinflammatory cytokines (IL10) were correlated with the induction of EMT transcription factors (TFs), Snail1, Zeb1, Twist1, in breast cancer patients.
Materials and Methods: From two laboratory-based ongoing studies at the MD Anderson Cancer Center, 41 BC patients were assessed for EMT-TFs in circulating CD45-ve cells (EMT-CTCs) and for serum proinflammatory cytokines before starting any treatment. 32 of 41 patients assessed for EMT had metastatic BC. EMT-CTCs were detected by qRT-PCR for the EMT-TFs Snail1, Zeb1 and Twist1 (Mego 2011; PMID 21387303) and serum cytokines were measured by Luminex bead array assay (MILLIPLEX™ MAP Human Cytokine/Chemokine Panel). Cytokine serum concentrations were compared with the median cytokine levels of healthy donors (HD). We examined the association of serum cytokines above the median HD levels and the presence of EMT-CTCs by non-parametric Mann-Whitney test with a statistical significance for p<.05.
Results: Of the 41 patients assessed for both serum cytokines and EMT-CTCs, 14 (34%) were positive for at least one EMT-TF, including 3 of 9 (33%) patients with no-metastatic BC and 11 of 32 (34%) patients with metastatic BC. We found that serum levels of IL1a, IL2, TGFα, and TNFβ in patients that were above the median levels of HD sera were higher in patients with EMT-CTCs in the blood (higher IL1a concentration in patients with over expression of Snail1, Zeb1, and Twist1; IL2 with Zeb1; TGFα with Snail1; TNFβ with Zeb1, and Twist1). Further, the higher ratio of proinflammatory/anti-inflammatory cytokines, was associated with the presence of at least one EMT-TF, e.g., IL8/IL10 (p=.005) and TNFα/IL10 (p=.037). Discussion: Patients with proinflammatory cytokine (IL1a, IL2, TGFα, and TNFβ) levels above the median levels of HD or who had a predominantly proinflammatory cytokine profile were more likely to have at least one EMT-TF in their blood. These data are consistent with the hypothesis that proinflammatory cytokines promote EMT, which may be involved in tumor aggressiveness and disease progression.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-02-07.
Collapse
|
73
|
Anfossi S, Giordano A, Cohen EN, Gao H, Cristofanilli M, Valero V, Alvarez RH, Hortobagyi GN, Woodward W, Ueno NT, Lee BN, Reuben JM. P3-03-02: Higher Expression Levels of Circulating miR-21, miR-19a and miR-10b Are Associated with High Risk Features in Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-03-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: MicroRNAs (miRs) have oncogenic and tumor-suppressor functions. MiR-21, miR-19a and miR-10b are overexpressed in breast cancer and regulate tumor cell migration, invasion and angiogenesis. We assessed the levels of miR-21, -19a, and -10b in sera of breast cancer patients and their association with the stage, histological type, hormonal receptor (HR) status and HER2 amplification in the primary tumor. Since circulating tumor cells (CTC) detected by CellSearch® are an independent and strong predictor of overall survival in metastatic breast cancer (MBC), we assessed the relationship between circulating miRs and CTCs.
Methods: The study consisted of 30 healthy donors (HD) and 95 breast cancer (BC) patients. Patients’ sera were collected before starting a new line of treatment. Total RNA was isolated, reverse transcribed to cDNA and then subjected to qRT-PCR for the detection of miR-21, -19a, -10b and -192 using the TaqMan MicroRNA Assay (Applied Biosystems, Foster City, CA). Mir-192 was used to normalize the expression levels of the other miRs. Fold-changes in expression of miRs were calculated using the 2−DCt method, where DCt= mean CTtarget-miRNA -mean CTmiR-192. CTCs were enumerated using CellSearch™ (Veridex LLC, Warren, NJ). Mann-Whitney U test was used to determine differences in serum miR expression levels between patients and HD.
Results: Of the 95 BC patients, 39 were non-MBC and 56 MBC. Patients grouped according to the receptor expression by immunohistochemical staining consisted of 27 HR+HER2−, 30 HR+HER2+, 20 HRHER2+, and 18 HRHER2− triple negative BC (TNBC). MiR-21 and miR-19a were higher in non-MBC patients than in HD (p=.001, p<.001, respectively). MiR-21, miR-19a and miR-10b levels were higher in metastatic patients than in HD (p<.001, p<.001, p=.038, respectively). MBC patients had a higher median level of miR-21 than that of non-MBC patients (p=.02). Patients with (HR+HER2+, HR−HER2+, TNBC) had significantly higher median levels of both miR-21 (p=.018; p=.009; p=.045) and miR-10b (p=.011; p=.014; p=.03) compared with HR+HER2− BC. HER2+ patients had higher median levels of both miR-21 and miR-10b than those of HER2− BC (p=.033; p=.01) and HD (p<.001; p=.009). Further, median miR-19a expression was higher in IBC patients than in non-IBC patients (p=.025). Finally, patients with <5 CTCs had a higher median expression level of miR-10b than that of patients with ≥5 CTCs (p=.042).
Discussion: High expression levels of miR-21, miR-19a and miR-10b in sera are observed in breast cancer patients, especially with advanced disease. HER2+ BC patients had higher serum levels of miR-21 and miR-10b than HER2−. IBC patients had a higher serum level of miR-19a than non-IBC patients. Moreover, patients with <5 CTCs had high serum levels of miR-10b that can be induced by Twist1 during the epithelial-mesenchymal transition (EMT) and, in part, explain the inability of CellSearch® to detect CTCs undergoing EMT.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-03-02.
Collapse
|
74
|
Cohen EN, Gao H, Lee BN, Giordano A, Tin S, Anfossi S, Parker CA, Cristofanilli M, Valero V, Alvarez RH, Hortobagyi GN, Woodward WA, Ueno NT, Reuben JM. P4-20-03: T-Cell Cytokine Production Related to Progression of Breast Cancer Patients. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-20-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Impaired immunosurveillance and immune dysregulation contribute to the pathogenesis and progression of breast cancer (BC). Upon activation, T cells synthesize inflammatory cytokines such as TNF-α that can promote or inhibit tumor growth. We therefore investigated T-cell cytokine syntheses as a predictor of disease progression.
Methods: We recruited 115 BC patients [25 with locally advanced breast cancer (LABC), 21 with metastatic breast cancer (MBC), 25 with non-metastatic inflammatory breast cancer (IBC), and 44 with metastatic IBC (mIBC)] and 31 healthy donors (HD) for this ongoing study. The tumor phenotype consisted of 69 hormone receptor (HR) positive (including 26 patients with HER2 positive disease), 16 HR negative but HER2+, 30 triple negative BC (TNBC). To evaluate T cell function, peripheral blood mononuclear cells from patients and HD were stimulated overnight with immobilized anti-CD3 and soluble anti-CD28 antibodies and assessed for the percentage of T cells that synthesized cytokines by multi-parameter flow cytometry. The associations of T cell cytokine production profile with patient progression free survival (PFS) were analyzed by Kaplan Meier Test.
Results: The median follow-up (FU) of 113 evaluable patients was 14.1 months with a median time to relapse of 10.5 months; 54 patients had stable disease (SD) and 59 patients had progression of disease (PD). In the entire cohort, on univariate analysis, metastasis, IBC, stage, and previous treatment predicted for worse PFS (p< 0.05). In non-metastatic patients (LABC+IBC), absolute count of anti-CD3 activated CD8+ T cells producing IL-17 was significantly higher in the SD patients compared with patient with PD (p=0.038), but it did not predict PFS (p=0.073). Similarly in metastatic patients, anti-CD3 activated CD4+ T cells producing TNF-α were significantly higher in patients with SD (p=0.025) and was predictive of longer PFS (p=0.033). Considering all patients with IBC (IBC + mIBC), although patients with PD had significantly fewer (percent and absolute number) anti-CD3 activated T cells capable of producing cytokines, this immune impairment was mostly related to metastasis and previous treatment. However, the percentage of anti-CD3 activated CD8+ T cells producing TNF-α was an independent positive prognostic indicator of PFS (p=0.002).
Conclusion: Higher than average cytokine syntheses by anti-CD3 activated T cells are significantly associated with longer PFS. These data are consistent with the hypothesis that an adaptive immune response can control disease progression.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-20-03.
Collapse
|
75
|
Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, Valero V, Fritsche HA, Cristofanilli M. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. Int J Cancer 2011; 130:1590-7. [PMID: 21469140 DOI: 10.1002/ijc.26111] [Citation(s) in RCA: 168] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2010] [Accepted: 02/03/2011] [Indexed: 12/17/2022]
Abstract
The detection of CTCs prior to and during therapy is an independent and strong prognostic marker, and it is predictive of poor treatment outcome. A major challenge is that different technologies are available for isolation and characterization of CTCs in peripheral blood (PB). We compare the CellSearch system and AdnaTest BreastCancer Select/Detect, to evaluate the extent that these assays differ in their ability to detect CTCs in the PB of MBC patients. CTCs in 7.5 ml of PB were isolated and enumerated using the CellSearch, before new treatment. Two cutoff values of ≥2 and ≥5 CTCs/7.5 ml were used. AdnaTest requires 5 ml of PB to detect gene transcripts of tumor markers (GA733-2, MUC-1, and HER2) by RT-PCR. AdnaTest was scored positive if ≥1 of the transcript PCR products for the 3 markers were detected at a concentration ≥0.15 ng/μl. A total of 55 MBC patients were enrolled. 26 (47%) patients were positive for CTCs by the CellSearch (≥2 cutoff), while 20 (36%) were positive (≥5 cutoff). AdnaTest was positive in 29 (53%) with the individual markers being positive in 18% (GA733-2), 44% (MUC-1), and 35% (HER2). Overall positive agreement was 73% for CTC≥2 and 69% for CTC≥5. These preliminary data suggest that the AdnaTest has equivalent sensitivity to that of the CellSearch system in detecting 2 or more CTCs. While there is concordance between these 2 methods, the AdnaTest complements the CellSearch system by improving the overall CTC detection rate and permitting the assessment of genomic markers in CTCs.
Collapse
|